Allison C Chin
Overview
Explore the profile of Allison C Chin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
325
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ip F, Ng Y, An H, Dai Y, Pang H, Hu Y, et al.
Neurosignals
. 2014 Aug;
22(1):52-63.
PMID: 25095809
Cycloastragenol (CAG) is an aglycone of astragaloside IV. It was first identified when screening Astragalus membranaceus extracts for active ingredients with antiaging properties. The present study demonstrates that CAG stimulates...
2.
Yung L, Lam W, Ho M, Hu Y, Ip F, Pang H, et al.
Planta Med
. 2011 Nov;
78(2):115-21.
PMID: 22083896
Two Chinese herb-derived small molecule telomerase activators, astragaloside IV (AG-IV) and cycloastragenol (CAG), have recently been shown to improve the proliferative response of CD8+ T lymphocytes from HIV-infected patients by...
3.
Zhu J, Lee S, Ho M, Hu Y, Pang H, Ip F, et al.
Drug Metab Pharmacokinet
. 2010 Sep;
25(5):477-86.
PMID: 20877137
Cycloastragenol (CAG) is the aglycone derivative of astragaloside IV which has recently been demonstrated to activate telomerase and represents a potential drug candidate for the treatment of degenerative diseases. In...
4.
Fauce S, Jamieson B, Chin A, Mitsuyasu R, Parish S, Ng H, et al.
J Immunol
. 2008 Nov;
181(10):7400-6.
PMID: 18981163
Telomerase reverse transcribes telomere DNA onto the ends of linear chromosomes and retards cellular aging. In contrast to most normal somatic cells, which show little or no telomerase activity, immune...
5.
Djojosubroto M, Chin A, Go N, Schaetzlein S, Manns M, Gryaznov S, et al.
Hepatology
. 2005 Aug;
42(5):1127-36.
PMID: 16114043
Most cancer cells have an immortal growth capacity as a consequence of telomerase reactivation. Inhibition of this enzyme leads to increased telomere dysfunction, which limits the proliferative capacity of tumor...
6.
Herbert B, Gellert G, Hochreiter A, Pongracz K, Wright W, Zielinska D, et al.
Oncogene
. 2005 Jun;
24(33):5262-8.
PMID: 15940257
The vast majority of human cancers express telomerase activity, while most human somatic cells do not have detectable telomerase activity. Since telomerase plays a critical role in cell immortality, it...
7.
Wang E, Wu K, Chin A, Chen-Kiang S, Pongracz K, Gryaznov S, et al.
Blood
. 2003 Sep;
103(1):258-66.
PMID: 12969977
The effects of telomerase inhibition with an oligonucleotide N3' --> P5' thiophosphoramidate (GRN163) complementary to the telomerase template region were examined on human multiple myeloma (MM) and non-Hodgkin lymphoma (NHL)...
8.
Asai A, Oshima Y, Yamamoto Y, Uochi T, Kusaka H, Akinaga S, et al.
Cancer Res
. 2003 Jul;
63(14):3931-9.
PMID: 12873987
Telomerase, the enzyme responsible for proliferative immortality, is expressed in essentially all cancer cells, but not in most normal human cells. Thus, specific telomerase inhibition is potentially a universal anticancer...